schizophrenia

Evenamide (NW-3509)– derived from Newron's ion channel program, tackles schizophrenia with its unique mechanism, balancing glutamate levels and blocking aberrant sodium channel activity to restore neuronal function without compromising normal excitability. Evenamide, based on a new concept in treating inadequat...

Brilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia. Brilaroxazine’s pharmacological profile sets it apart from traditional antipsychotics. Operating as a partial agonist at D2/3/4 and 5-HT1A/2A recept...

Fifteen years after its first FDA approval for treating schizophrenia with Fanapt (iloperidone), Vanda Pharmaceuticals has achieved another success. Fanapt is a type of antipsychotic medication that deviates from the usual and has been administered to individuals with schizophrenia for their immediate treatment fol...

Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna’s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owne...

FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS The FDA has granted priority review to a supplemental biologics license application (sBLA) seeking to expand the current indication of luspatercept-aamt (Reblozyl) to include treatment of anemia in patients with very ...

FDA Approves Luye Pharma’s Rykindo for Schizophrenia Luye Pharma has received its first FDA approval for Rykindo, an injectable formulation of the antipsychotic risperidone administered every two weeks. Rykindo has been approved by the US Food and Drug Administration for the treatment of schizophrenia as well as...

Schizophrenia affects approximately 24 million people worldwide, or 1 in every 300 people (0.32%). In adults, this rate is 1 in 222 (0.45%). It is not as widespread as many other mental disorders. Onset occurs most frequently in late adolescence and the twenties, and it occurs earlier in men than in women. Schiz...

FDA Approves BioXcel’s Agitation Drug Igalmi BioXcel Therapeutics has received FDA clearance for its first drug, Igalmi, as a treatment for agitation in persons with Schizophrenia or Bipolar Disorder. Igalmi (dexmedetomidine) is the first drug approved for this application that comes in the form of a tablet that...

Progress is driven by innovation. When it comes to developing novel medications and therapeutic biological products, the FDA's Center for Drug Evaluation and Research (CDER) assists the pharmaceutical sector at every stage of the process. CDER offers scientific and regulatory assistance needed to bring innovative m...

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...